Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Kymera Therapeutics announced that Phase 1b data for its lead asset KT-621 will be featured in a late-breaking oral presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The data demonstrates deep STAT6 degradation in skin and blood, along with significant downregulation of Type 2 inflammatory biomarkers and gene signatures associated with itch and fibrosis.
Key figures
- Drug Name
- KT-621
- Phase Of Trial
- Phase 1b
- Treatment duration
- 4 weeks
- Patient population size
- 140 million
- Phase2b ad data expected
- mid-2027
- Phase2b asthma data expected
- late-2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.